AZ’s Tagrisso gets new early lung cancer use in USAstraZeneca’s Tagrisso (osimertinib) has been approved by the FDA in a new lung cancer indication that extends its Share XAZ’s Tagrisso gets new early lung cancer use in UShttps://pharmaphorum.com/news/azs-tagrisso-gets-new-early-lung-cancer-use-in-us/
Amgen files KRAS trailblazer sotorasib with FDA for lung cancerAmgen has filed its groundbreaking KRAS inhibiting drug sotorasib with the FDA for a group of lung cancer Share XAmgen files KRAS trailblazer sotorasib with FDA for lung cancerhttps://pharmaphorum.com/news/amgen-files-kras-inhibitor-with-fda/
Merck & Co buys cancer biotech VelosBio for $2.75bnMerck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion Share XMerck & Co buys cancer biotech VelosBio for $2.75bnhttps://pharmaphorum.com/news/merck-co-buys-cancer-biotech-velosbio-for-2-75bn/
FDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancerThe FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung Share XFDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancerhttps://pharmaphorum.com/news/fda-grants-fast-review-for-astrazenecas-tagrisso-in-early-stage-lung-cancer/
Amgen offers hope in KRAS-mutated cancer with sotorasib read-outLast year Amgen intrigued scientists and investors alike after announcing data showing it had produced the first drug Share XAmgen offers hope in KRAS-mutated cancer with sotorasib read-outhttps://pharmaphorum.com/news/amgen-offers-hope-in-kras/
Blueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drugCancer drugs firm Blueprint Medicines has gained a second US approval, with its Gavreto (pralsetinib) daily pill that Share XBlueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drughttps://pharmaphorum.com/news/blueprint-and-roche-take-on-lilly-as-fda-approves-ret-targeting-lung-cancer-drug/
AZ aims to cut cancer clinic visits with new Imfinzi regimenThe FDA is to review data supporting AstraZeneca’s Imfinzi (durvalumab) cancer immunotherapy in a new four-week regimen that Share XAZ aims to cut cancer clinic visits with new Imfinzi regimenhttps://pharmaphorum.com/news/az-aims-to-cut-cancer-clinic-visits-with-new-imfinzi-regimen/
AstraZeneca inks $6bn cancer drug deal with Daiichi SankyoAstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, Share XAstraZeneca inks $6bn cancer drug deal with Daiichi Sankyohttps://pharmaphorum.com/news/astrazeneca-inks-6bn-cancer-drug-deal-with-daiichi-sankyo/
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancersWith an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now Share XASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancershttps://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/
